Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients*†‡‡

S. M. Garonzik,*1 J. Li,2† V. Thamlikitkul,3 D. L. Paterson,4 S. Shoham,5 J. Jacob,2 F. P. Silveira,6‡ A. Forrest,1‡ and R. L. Nation2*‡

School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, New York1; Facility for Anti-infective Drug Development and Innovation, Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia2; Division of Infectious Diseases and Tropical Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand3; The University of Queensland Clinical Research, Royal Brisbane and Women’s Hospital, Brisbane, Australia4; Washington Hospital Center, MedStar Clinical Research Center, Washington, DC5; and Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania6

Received 13 December 2010/Returned for modification 13 March 2011/Accepted 28 April 2011

With increasing clinical emergence of multidrug-resistant Gram-negative pathogens and the paucity of new agents to combat these infections, colistin (administered as its inactive prodrug colistin methanesulfonate [CMS]) has reemerged as a treatment option, especially for critically ill patients. There has been a dearth of pharmacokinetic (PK) data available to guide dosing in critically ill patients, including those on renal replacement therapy. In an ongoing study to develop a population PK model for CMS and colistin, 105 patients have been studied to date; these included 12 patients on hemodialysis and 4 on continuous renal replacement therapy. For patients not on renal replacement, there was a wide variance in creatinine clearance, ranging from 3 to 169 ml/min/1.73 m². Each patient was treated with a physician-selected CMS dosage regimen, and 8 blood samples for PK analysis were collected across a dosage interval on day 3 or 4 of therapy. A linear PK model with two compartments for CMS and one compartment for formed colistin best described the data. Covariates included creatinine clearance on the total clearance of CMS. Model-fitted parameter estimates were used to derive suggested loading and maintenance dosing regimens for various categories of patients, including those on hemodialysis and continuous renal replacement. Based on our current understanding of colistin PK and pharmacodynamic relationships, colistin may best be used as part of a highly active combination, especially for patients with moderate to good renal function and/or for organisms with MICs of ≥1.0 mg/liter.

There has been an increasing clinical emergence of multidrug-resistant (MDR) Gram-negative pathogens, in particular Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, and this is especially of concern for critically ill patients (19, 30). Infections caused by these organisms are increasingly difficult to treat due to a wide variety of resistance mechanisms. With a paucity of new drugs available to treat infections caused by these MDR organisms, colistin, also known as polymyxin E, which was first introduced in the late 1950s, has reemerged as a treatment of choice and often as the only antibiotic active against these organisms (14, 26, 33). Colistin is available for parenteral administration as colistin methanesulfonate (CMS), an inactive prodrug that is less nephrotoxic than colistin (7, 25). Because it has been more than 50 years since CMS became available for clinical use, it has never been subjected to contemporary drug development procedures. As a result, there are very limited pharmacokinetic (PK) data available to guide appropriate CMS dosage selection, especially in critically ill patients. Early studies, including those used for current product labeling, utilized nonspecific microbiological assays which are not able to differentiate colistin present in biological samples at the time of collection from that formed from CMS in vitro during the incubation phase of microbiological assays. Current dosing guidelines therefore are not scientifically based, have been found to be inappropriate, and have led to treatment failure as well as emergence of resistance (1, 6, 20).

The need to administer antibiotics in critically ill patients based upon PK, pharmacodynamic (PD), and toxicodynamic (TD) principles in order to optimize the benefit and minimize the potential for development of resistance has been highlighted recently (30). The relatively recent development of separate assays for colistin and CMS in biological fluids...
(17, 21–22, 32) has provided some insight into the disposition of CMS and formed colistin in small populations of critically ill patients (total of 32) with near-normal renal function (29, 31). The removal of CMS and colistin by continuous renal replacement therapy and intermittent hemodialysis has been assessed in just three critically ill patients (27–28). As a result, there is a major paucity of information on the disposition of the prodrug CMS and formed colistin in critically ill patients across a wide range of renal function. The aims of this study were to develop a population PK model for CMS and colistin in a larger population of critically ill patients with a wider range of renal function more typical of this population, including those receiving renal replacement therapy. This would permit characterization of the patient covariates influencing the disposition of CMS and formed colistin and, by integrating the PK results with literature PD data, development of improved dosing guidelines for use in this difficult-to-treat population. This report presents the results for 105 critically ill patients from an ongoing study that will recruit a total of 238 patients to define the population PK/PD/TD of CMS and formed colistin. The interim dosing suggestions contained herein provide important information for clinicians to assist in the use of intravenous CMS/colistin in this difficult-to-manage population.

**MATERIALS AND METHODS**

**Patients and study design.** This was an open-label population PK study conducted at two sites in the United States and one in Thailand. Patients were eligible for enrollment in the study if they were ≥18 years old, receiving CMS as part of their clinical care for treatment of bloodstream infection or pneumonia due to a Gram-negative bacillus lacking susceptibility to all of the antibiotics cefepime or ceftazidime, imipenem or meropenem, piperacillin-tazobactam, and ciprofloxacin or levofloxacin, and had adequate venous access to enable collection of blood for determination of CMS and formed colistin in plasma. Patients who were pregnant or breastfeeding, were concomitantly receiving CMS/colistin or polymyxin B delivered directly into the respiratory tract, or had cystic fibrosis were excluded. Data collected included demographic information, APACHE II (acute physiology and chronic health evaluation II) scores, serum creatinine, comorbidities, use of immunosuppressives, and presence and type of renal replacement (intermittent hemodialysis [HD] or continuous renal replacement therapy [CRRT]). Informed consent was obtained for all patients, and the study was approved by the ethics committee of each institution.

**CMS administration.** CMS (Colistate [Atlantic Pharmaceutical Co., Bangkok, Thailand], and colistimethate for injection [Paddock Laboratories, Inc., MN and X-Gen Pharmaceuticals, Inc., Big Flats, NY]) was administered intravenously as a short-term infusion (range of infusion durations, 9 to 180 min) every 8 to 24 h according to a dosage regimen determined by the respective treating physician. The dose of CMS was expressed as colistin base activity (CBA): 150 mg CBA is equivalent to approximately 5 million units (MU) of CMS (26) and approximately 400 mg CMS sodium.

**Pharmacokinetic sampling.** Eight samples of blood (each 3 ml) were collected across a dosage interval on day 3 to 4 of CMS therapy. Samples were collected immediately prior to a dose, at the end of the CMS infusion, and at the following nominal times thereafter: 0.5, 1, 2, 4, 8, and 12 h or immediately prior to the next dose if CMS was not being administered every 12 h. The actual times of CMS administration and blood sampling were recorded. Samples were collected in heparinized blood collection tubes, placed on ice, and centrifuged at 4°C within 1 h of collection. The resulting plasma was stored at −70 to −80°C to prevent in vitro conversion of CMS to colistin (11). For patients on either HD or CRRT, the total volume of dialysate collected across a collection interval was measured or calculated from known flow rates. For subjects on HD, “spot” samples of dialysate were collected just after the start of the dialysis session, once every hour during dialysis, and just prior to the end of the session (typically, 4 such samples were collected); blood samples were also collected at the start and end of the session in those cases where the HD occurred on a different day from that for the collection of the eight blood samples mentioned above. For subjects on CRRT, “spot” dialysate samples (approximately 8) were collected at the same nominal times as for the eight interdosing blood samples described above.

**Determination of CMS and colistin concentrations in plasma.** CMS and colistin concentrations in plasma were quantified by previously reported high-performance liquid chromatographic methods (21–22). Plasma CMS and colistin concentrations were quantified within 4 months of collection to avoid in vitro conversion of CMS to colistin (11). The accuracies of the plasma colistin assay at the low, medium, and high quality control concentrations were 106%, 100%, and 103% of target concentrations, respectively, with corresponding precision (CV) of 6.27%, 7.85%, and 6.46%. The respective values for the low, medium, and high quality control concentrations for CMS were accuracies of 103%, 99%, and 98% with precision of 11.8%, 6.65%, and 6.46%. The limits of quantification were 0.10 mg/liter for colistin and 0.30 mg/liter for CMS.

**Pharmacometric methods.** A nonlinear mixed-effects modeling tool, S-ADAPT (Monte Carlo parametric expectation maximization [MCPEM]), was used to analyze the plasma concentration-versus-time data for both CMS and formed colistin (3, 8). The nonlinear mixed-effects models were explored for the plasma concentration-time profiles for CMS and colistin, with linear or nonlinear (saturable) elimination. The model was built in a piecewise manner; first the model for CMS was developed, after which colistin data were included and the model characterizing colistin disposition was built. These models were first fit to the data for patients not on renal replacement. Subsequently, the “best-fit” model was fit to the data for patients on HD and CRRT by including an extracorporeal clearance which played a role in the plasma disposition of CMS and colistin. Attempts to model the plasma and dialysate data in patients on renal replacement were not successful. The modeled fits were inferior for some patients (compared with those from modeling of plasma data only), probably due to the proportion of dialysate concentrations that were below the limit of quantification. Subsequently, the extracorporeal clearances of CMS and colistin were modeled upon plasma concentration data only. Additional modifications to this model were evaluated. These modifications included the presence or absence of transit compartments to characterize a decrease in plasma concentrations of CMS and the slow rise in plasma concentrations of colistin for subjects with renal failure. As a final step, the models for subjects on renal replacement and those not on renal replacement were combined and comodeled to allow for maximal benefit of population PK. Residual error models evaluated were proportional or additive plus proportional. The interindividual variability was assumed to be log-normally distributed. Plasma concentrations below the limit of quantification were handled by the Beal M3 method (5).

**Covariate model building.** Covariate covariates that were evaluated for their possible effect on CMS and colistin disposition included the following: body size (height, body surface area [BSA]), body weight, age, sex, body mass index [BMI], race, ethnicity, race, gender, age, creatinine clearance (CrCL), and APACHE II score on clearance; and body size (actual and ideal weight, BSA, BMI) on volume of distribution. Calculation of CrCL was done by use of the Jelliffe equation (18) for patients with unstable renal function. Model evaluation was performed via nonparametric bootstrap techniques using 500 randomly sampled data sets. Each new data set contained the same proportion of patients on HD or on CRRT as the original data set. After building the population PK model for CMS and colistin, we applied it to the development of suggestions for both loading and maintenance doses of CMS designed to achieve a desired target plasma colistin concentration. First, each individual’s fitted PK parameter estimates from the final population PK model were used to compute that subject’s ideal loading and maintenance doses to achieve a user-specified target plasma colistin concentration. Any and all covariates for CMS and colistin PK which were also significantly related to the ideal dose were incorporated into the dosing algorithms. Further detail is provided in Results.

**RESULTS**

**Patient characteristics.** A total of 105 patients studied to date (recruited between February 2009 and July 2010) were included in this study, of whom 12 were receiving HD and 4 were on CRRT (3 on continuous veno-venous hemodialysis...
TABLE 1. Patient characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median (range)</td>
<td></td>
</tr>
<tr>
<td>Age (yr)</td>
<td>71 (19–92)</td>
</tr>
<tr>
<td>Wt (kg)</td>
<td>59.1 (30.0–106.4)</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>162.0 (140.0–184.5)</td>
</tr>
<tr>
<td>APACHE II score</td>
<td>21 (4–38)</td>
</tr>
<tr>
<td>Serum creatinine (mg/dl)</td>
<td>1.2 (0.2–10.3)</td>
</tr>
<tr>
<td>Creatinine clearance (ml/min/1.73 m²)</td>
<td>28.7 (0–169)</td>
</tr>
</tbody>
</table>

No. (%) of patients

<table>
<thead>
<tr>
<th>Sex</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>68 (64.8)</td>
</tr>
<tr>
<td>Female</td>
<td>37 (35.2)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Comorbidity</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>24 (22.9)</td>
</tr>
<tr>
<td>Malignancy</td>
<td>22 (21.0)</td>
</tr>
<tr>
<td>Immunosuppression</td>
<td>13 (12.4)</td>
</tr>
<tr>
<td>Hepatic failure</td>
<td>10 (9.5)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CMS treated with</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacteremia</td>
<td>11 (10.5)</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>94 (89.5)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Source of bacteremia</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumonia</td>
<td>1 (9.1)</td>
</tr>
<tr>
<td>Intra-abdominal</td>
<td>5 (45.5)</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>2 (18.2)</td>
</tr>
<tr>
<td>Unknown</td>
<td>3 (27.3)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Renal replacement therapy</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemodialysis</td>
<td>12 (11.4)</td>
</tr>
<tr>
<td>Continuous renal replacement</td>
<td>4 (3.8)</td>
</tr>
</tbody>
</table>

TABLE 1. Patient characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median (range)</td>
<td></td>
</tr>
<tr>
<td>Age (yr)</td>
<td>71 (19–92)</td>
</tr>
<tr>
<td>Wt (kg)</td>
<td>59.1 (30.0–106.4)</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>162.0 (140.0–184.5)</td>
</tr>
<tr>
<td>APACHE II score</td>
<td>21 (4–38)</td>
</tr>
<tr>
<td>Serum creatinine (mg/dl)</td>
<td>1.2 (0.2–10.3)</td>
</tr>
<tr>
<td>Creatinine clearance (ml/min/1.73 m²)</td>
<td>28.7 (0–169)</td>
</tr>
</tbody>
</table>

No. (%) of patients

<table>
<thead>
<tr>
<th>Sex</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>68 (64.8)</td>
</tr>
<tr>
<td>Female</td>
<td>37 (35.2)</td>
</tr>
</tbody>
</table>

Plasma concentrations of CMS and colistin. A total of 851 plasma samples were available for each of CMS and colistin; no samples were excluded from the modeling analyses. Plasma concentration-time profiles of CMS and formed colistin for all patients are presented in Fig. 1. For each patient, the profile for formed colistin was much flatter than that for CMS, consistent with the active antibacterial having a longer terminal half-life than the prodrug. There was substantial interpatient variability in the plasma concentrations of both CMS and colistin achieved from the empirically selected CMS dosage regimens. The area under the plasma concentration-versus-time curve over a day (AUC0–24) for formed colistin ranged from 11.5 to 225 mg · h/liter. Division of each AUC0–24 value by 24 h generates the average steady-state plasma concentration (C_{ss,avg}) of colistin for each patient; the range of the colistin C_{ss,avg} across all patients was 0.48 to 9.38 mg/liter (median, 2.36 mg/liter). There was a strong inverse trend between the colistin C_{ss,avg} and the CrCL (Fig. 2); the corresponding relationship between the physician-selected daily dose of CBA and CrCL is shown in the same figure.

Population PK analysis. The disposition of CMS and formed colistin was best described by a linear model comprising two and one compartments, respectively. Equations 1 to 3 below represent the differential equations for the disposition of CMS and colistin. CMSc is the mass of CMS in the central compartment, CMSp is the mass of CMS in the peripheral compartment, and “colistin” in equation 3 is the mass of colistin in the single compartment for colistin. V1 and V2 represent the central and peripheral volumes for CMS, and V3 represents the volume of distribution for colistin. R(1) represents the infusion rate of CMS, and CLD1 represents the distributional clearance between the central and peripheral compartments for CMS. CLTCMS and CLTC refer to the total intrinsic clearance for CMS and colistin. CLTCMS was modeled as the sum of renal clearance and a nonrenal clearance (CLNR_{CMS}), with a portion of the latter

[CVVHD] and 1 on continuous veno-venous hemofiltration [CVVH]). Patient characteristics are summarized in Table 1. The HD patients had dialysate flow rates ranging from 500 to 600 ml/min, blood flow rates ranging from 200 to 350 ml/min, membrane surface areas ranging from 1.5 to 1.9 m², and membrane type SF190E, Rex 18, or SF150; the frequency of HD ranged from daily to twice weekly, and session duration was 3 h 15 min to 4 h 15 min (median, 4 h). All 3 CVVHD patients had dialysate flow rates of 42 ml/min, blood flow rates of 150 ml/min, membrane surface area of 0.9 m², and membrane type ANG9HF. The median daily dose of colistin base activity across the 105 patients was 200 mg (range, 75 to 410 mg).

FIG. 1. Steady-state plasma concentration-time profiles of the prodrug CMS (A) or formed colistin (B) in 105 critically ill patients (89 not on renal replacement, 12 on intermittent HD, and 4 on CRRT). The physician-selected daily doses of colistin base activity (CBA) ranged from 75 to 410 mg/day; the dosage intervals ranged from 8 to 24 h, and hence the interdosing blood sampling interval spanned the same range.
forming colistin. Colistin clearance and volume of distribution ($V_3$) are thus conditioned on the unknown fraction ($f_m$) of the nonrenal clearance of CMS that actually forms colistin (this $f_m$ is not the fraction of the total administered dose of CMS converted to colistin). For patients on hemodialysis, HD clearance for CMS ($CL_{HDCMS}$) and colistin ($CL_{HDC}$) also played a role in the disposition of CMS and colistin. These clearance values were estimated during dialysis and set to zero when dialysis was turned off. Similarly, for patients on CRRT, CLRRTCMS and CLRRTC also played a role in the disposition of CMS and colistin.

\[
\frac{dCMSc}{dt} = R(1) - CLD1 \times \left( \frac{CMSc}{V_1} - \frac{CMSp}{V_2} \right) - (CL_{CMS} + CL_{HDCMS} + CLR_{RT CMS}) \times \frac{CMSc}{V_1} \tag{1}
\]

\[
\frac{dCMSp}{dt} = CLD1 \times \left( \frac{CMSc}{V_1} - \frac{CMSp}{V_2} \right) \tag{2}
\]

\[
\frac{dColistin}{dt} = CL_{NRCMS} \times \frac{CMSc}{V_1} - (CL_{C} + CL_{HDC} + CLR_{RT C}) \times \frac{Colistin}{V_3} \tag{3}
\]

In order to inform the model and constrain clearance due to CRRT to be smaller than clearance due to dialysis in HD patients, clearances of CMS and colistin due to CRRT were modeled as a fraction ($FRRT$) of the respective clearances due to dialysis in HD patients. The equations below define the clearances due to CRRT.

\[
CLR_{RT CMS} = CL_{HDCMS} \times FRRT \tag{4}
\]

\[
CLR_{RT C} = CL_{HDC} \times FRRT \tag{5}
\]

A thorough PK covariate analysis was performed for candidate covariates (both as fixed and random effects where appropriate). Total CMS clearance ($CL_{TCMS}$) was modeled as a function of $CrCL$ and two random effects, $CL_{RSLOPE}$ and $CL_{NRCMS}$, using equation 6 below.

\[
CL_{TCMS} = CrCL \times CL_{RSLOPE} + CL_{NRCMS} \tag{6}
\]

The central compartment volume for CMS ($V_1$) was modeled as a function of weight (fixed effect) and centered using a value approximating the median weight, 60.0 kg, using equation 7 below. $V_1_{POP}$ is a standard “population” volume of distribution value (liters/60 kg) for the central volume of CMS, which was allowed to vary as a function of body weight.

\[
V_1 = V_1_{POP} \times \left( \frac{WTKG}{60.0} \right) \tag{7}
\]

The apparent colistin clearance ($CLTC/fm$) was modeled as a sum of two fixed effects, a renally dependent component ($CLR_{CSL_POP}$) and a nonrenally dependent component ($CL_{NRC_POP}$), using equation 8 below.

\[
CL_{TC} = CrCL \times CLR_{CSL_POP} + CL_{NRC_{POP}} \tag{8}
\]

The derived terminal half-lives for CMS and colistin in patients not on CRRT were also dependent on $CrCL$: for 20 patients with $CrCL$ of $<10$ ml/min/1.73 m$^2$, the median half-life (10th to 90th percentile) for CMS was 11 (6.3 to 43) h and that for colistin was 13 (7.0 to 18) h; for 62 patients with $CrCL$ of 11 to 69 ml/min/1.73 m$^2$, the half-life for CMS was 5.6 (3.2 to 14) h and that for colistin was 13 (8.2 to 19) h; for 19 patients with $CrCL$ of $>70$ ml/min/1.73 m$^2$, the half-life for CMS was 4.6 (1.9 to 9.1) h and that for colistin was 9.1 (6.3 to 12) h.

All model-fitted parameters were estimated with good to excellent precision (standard errors between 3.1 and 44%), with core parameters having moderate interindividual variability (23 to 70%) (Table 2). Representative individual fits are presented in Fig. 3. The overall goodness-of-fit plots (observed
versus fitted concentrations) for both CMS and colistin indicated that the individual fits were precise and unbiased, with \( r^2 \) values of 0.94 for both CMS and colistin (data not shown).

The results of the bootstrap analysis (Table 2) agreed well with the final model estimates (for parameters not relating to renal replacement), with the median value from the bootstrap runs being within 1 to 3% of the final estimate, with a 10 to 90% confidence interval (CI) for all parameter means (except CLRCSL_POP/fm) no more than 22.3% below or 24.6% above the final model estimate. Similar precision was also noted for the variance (not shown) around the estimates, with the median value from the bootstrap being within 1 to 6% of the final model-fitted estimate with a 10 to 90% CI no more than 48.2% above or 48.5% below the fitted value.

Development of CMS dose suggestions for various categories of patients. The population PK models for patients not on renal replacement and those receiving HD or CRRT were then used to derive maintenance dosing suggestions for CMS in critically ill patients to achieve a desired “target” \( C_{ss,avg} \) of colistin in plasma.

For those patients not on renal replacement (\( n = 89 \)) together with those receiving HD (\( n = 12 \)), each patient’s “ideal” maintenance dose of CMS (expressed as CBA) was computed, based on their individual fitted PK parameter estimates from the population PK model and a chosen target plasma colistin \( C_{ss,avg} \). The “ideal” maintenance dose of CBA required to achieve each 1.0 mg/liter of target colistin \( C_{ss,avg} \) for each patient was then regressed against the corresponding CrCL, adjusted by differentially weighing the cost of being above

### Table 2. Population PK model-fitted parameters

<table>
<thead>
<tr>
<th>Category</th>
<th>Parameter (units)</th>
<th>Model-fitted result</th>
<th>Bootstrap result*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of subjects</td>
<td>Estimate</td>
<td>% SE</td>
</tr>
<tr>
<td>CMS</td>
<td>( V_1 ) (liters)</td>
<td>105</td>
<td>11.5</td>
</tr>
<tr>
<td></td>
<td>( V_2 ) (liters)</td>
<td>105</td>
<td>18.7</td>
</tr>
<tr>
<td></td>
<td>CLD1 (liters/h)</td>
<td>105</td>
<td>7.98</td>
</tr>
<tr>
<td>Random</td>
<td>CLR_SLOPE (liters/h/CrCL)</td>
<td>89</td>
<td>0.0613</td>
</tr>
<tr>
<td>effects</td>
<td>CLNRCMS (liters/h)</td>
<td>105</td>
<td>1.90</td>
</tr>
<tr>
<td>CMS</td>
<td>( V_3/fm ) (liters)</td>
<td>105</td>
<td>45.1</td>
</tr>
<tr>
<td></td>
<td>CLT_C/fm (liters/h)</td>
<td>105</td>
<td>2.72</td>
</tr>
<tr>
<td>Colistin</td>
<td>( V_1 )pop (liters/60 kg)</td>
<td>105</td>
<td>11.9</td>
</tr>
<tr>
<td>Fixed</td>
<td>CLRCSL_POP/fm (liters/h/CrCL)</td>
<td>89</td>
<td>0.0147</td>
</tr>
<tr>
<td>effects</td>
<td>CLNRC_f/m (liters/h)</td>
<td>105</td>
<td>2.19</td>
</tr>
<tr>
<td>Renal</td>
<td>CLR CMS (liters/h)</td>
<td>16</td>
<td>5.69</td>
</tr>
<tr>
<td>replacement</td>
<td>CLHD_CMS (liters/h)</td>
<td>16</td>
<td>3.40</td>
</tr>
<tr>
<td></td>
<td>CLHD_C (liters/h)</td>
<td>16</td>
<td>3.40</td>
</tr>
<tr>
<td></td>
<td>CLRRTCMS (liters/h)</td>
<td>4</td>
<td>3.85</td>
</tr>
<tr>
<td></td>
<td>CLRRTC (liters/h)</td>
<td>4</td>
<td>2.06</td>
</tr>
<tr>
<td>Error</td>
<td>SD_SLOPE_CMS</td>
<td>105</td>
<td>0.183</td>
</tr>
<tr>
<td>variance</td>
<td>SD_SLOPE_C</td>
<td>105</td>
<td>0.099</td>
</tr>
<tr>
<td></td>
<td>SD_INTERCEPT</td>
<td>Fixed at LOQ</td>
<td>Fixed at LOQ</td>
</tr>
</tbody>
</table>

* Estimates refer to the geometric mean of the estimates in the population. This may refer to the entire 105 subjects, 89 subjects not on any renal replacement, 16 subjects on some form of renal replacement, or 4 subjects on CRRT and is specified by the “No. of subjects” column. % SE refers to the standard error or the precision of the estimates, while % IIV refers to the interindividual variability in the population. LOQ refers to the limit of quantification.

* For the two RRT groups, the geometric mean, % SE, and % IIV are based on summary statistics of the post hoc estimates in the indicated population.

* Bootstrap results are expressed as a % of the model-fitted estimates.

![FIG. 3. Representative individual population PK model fits of CMS (A, C, and E) or formed colistin (B, D, and F) in critically ill patients. Panels A and B are representative of a subject not on renal replacement, C and D are representative of a subject on HD, and E and F are representative of a subject on CRRT.](image-url)
The final weighted regression maximized the cases within the desired window and minimized the resulting cost function (balancing the risks of being below versus being above the window, favoring the latter by approximately 2:1). The resultant relationship (Fig. 4) forms the basis of a maintenance dosing algorithm for critically ill patients in the two above-mentioned categories (Table 3, equation 10). It should be noted that the “ideal” maintenance dose of CBA required to achieve each 1.0 mg/liter of colistin target \( C_{ss,avg} \) for each of the 12 HD patients ranged from 23 to 41 mg CBA per day (median, 30 mg CBA per day). This median accords well with the daily maintenance dose of CBA calculated using equation 10 (Table 3) in a patient with a CrCl of zero.

Our population PK modeling in the present study (Table 2) and previous findings (15, 28) indicate that both CMS and colistin are efficiently cleared by hemodialysis. In order to replace CMS and colistin lost due to hemodialysis and maintain a colistin \( C_{ss,avg} \) on an HD day similar to that on a non-HD day, the fitted clearances due to HD for each of CMS and colistin were used to determine the magnitude of a CMS supplemental dose. A higher supplemental dose of CMS is required if it is administered during the last hour of the HD session compared with administration after the end of the HD session (Table 3). It was assumed that the HD session occurs toward the end of a CMS maintenance dosage interval. The “ideal” maintenance doses computed from the population PK model for 4 patients on CRRT (3 CVVHD and 1 CVVH) ranged from 112 to 260 (median, 192) mg CBA/day per 1.0 mg/liter colistin target \( C_{ss,avg} \), leading to the suggested daily

![FIG. 4. Relationship between the “ideal” maintenance dose of CMS (expressed as mg per day of colistin base activity [CBA] per each 1.0 mg/liter of colistin \( C_{ss,avg} \) target) and creatinine clearance in 101 critically ill patients (89 not on renal replacement and 12 on HD).](image)

<table>
<thead>
<tr>
<th>TABLE 3. Suggested loading dose and daily maintenance doses of CMS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Loading dose</strong></td>
</tr>
<tr>
<td>Loading dose</td>
</tr>
<tr>
<td>Maintenance dose</td>
</tr>
<tr>
<td>Receiving intermittent hemodialysis</td>
</tr>
<tr>
<td>Receiving continuous renal replacement</td>
</tr>
</tbody>
</table>

---

\( ^a \) Expressed as mg of colistin base activity (CBA) for various categories of critically ill patients. The suggested maintenance daily dose would commence 24 h after administration of a CMS loading dose. Example: To target a colistin \( C_{ss,avg} \) of 2.5 mg/liter, a 55-kg patient with a CrCl of 40 ml/min/1.73 m\(^2\) would receive a loading dose of 275 mg CBA followed in 24 h by commencement of a maintenance regimen of 225 mg CBA/day in 2 to 3 equally divided doses. \( ^b \) Colistin \( C_{ss,avg} \) target is expressed in mg/liter. This target should be based on MIC, site, and severity of infection. \( ^c \) Use the lower of ideal or actual body weight, expressed in kg. At this time, we suggest caution in the use of a loading dose greater than 300 mg CBA (see the text for more details). \( ^d \) Based upon the population PK analysis for 101 critically ill patients not on continuous renal replacement therapy. Colistin \( C_{ss,avg} \) target expressed in mg/L. Creatinine clearance (CrCl) expressed in ml/min/1.73 m\(^2\). Although the Jelliffe equation was used to estimate CrCl in this study, other means (e.g., Cockcroft and Gault equation) may be used to estimate CrCl which would then be normalized to a body surface area of 1.73 m\(^2\). See text for caveat regarding use of the algorithm in patients with CrCl values > 70 ml/min/1.73 m\(^2\) or when targeting a “high” colistin \( C_{ss,avg} \), both being circumstances where the algorithm may predict daily doses of CBA substantially greater than the current upper limit in the product label. \( ^e \) Based upon use of equation 10 and setting CrCl to zero. \( ^f \) Supplemental dose of CMS to achieve a similar colistin \( C_{ss,avg} \) on an HD day as occurs on a non-HD day. It is assumed that the hemodialysis session occurs toward the end of a CMS dosage interval. \( ^g \) Based on the population PK analysis for 4 critically ill patients receiving continuous renal replacement therapy.
The suggested dose intervals are dependent on CrCl; see Table 3.

The maintenance dosing suggestions for various categories of critically ill patients (Table 3) were then applied to all patients studied to date, using a colistin \(C_{ss,avg}\) target of 2.5 mg/liter, corresponding to a steady-state colistin AUC\(_{0-24}\) of 60 mg·h/liter; the colistin \(C_{ss,avg}\) target of 2.5 mg/liter was very similar to the median \(C_{ss,avg}\) of 2.36 mg/liter achieved in the 105 patients with the physician-selected maintenance doses of CMS, but the predicted variances were substantially lower. Among those not on any renal replacement plus those on HD, 3/101 (~3%) of patients are predicted to have achieved a colistin \(C_{ss,avg}\) of 0.5 to 1 mg/liter, 86/101 (~85%) a colistin \(C_{ss,avg}\) of 1.0 to 4.0 mg/liter, and 12/101 (~12%) a colistin \(C_{ss,avg}\) of >4.0 mg/liter. Among those on HD, all 12 patients would have been predicted to achieve a colistin \(C_{ss,avg}\) between 1.9 and 3.4 mg/liter. Patients on CRRT required a maintenance dose ~6-fold higher than that required by an HD patient on a nondialysis day. With a dose of 480 mg CBA per day, aiming to achieve a colistin \(C_{ss,avg}\) of 2.5 mg/liter, all 4 CRRT patients would be predicted to achieve \(C_{ss,avg}\) concentrations of colistin between 1.9 and 4.2 mg/liter.

The predicted steady-state colistin AUC\(_{0-24}\) values, from the above algorithm-predicted maintenance doses applied back to all 105 patients, were then linked with PD models for 3 strains of *A. baumannii* (MICs of 0.5, 1.0, and 1.0 mg/liter) and 3 strains of *P. aeruginosa* (MICs of 0.5, 1.0, and 1.0 mg/liter) previously studied using neutropenic mouse thigh and lung infection models (12–13). In both murine models, the most predictive PK/PD index for antibacterial effect of colistin against both species was the ratio of AUC\(_{0-24}\) (unbound) to MIC (12–13). At this time, the plasma binding of colistin in critically ill patients is not known, because the concomitant presence of variable concentrations of CMS in plasma samples and other factors pose significant technical difficulties. Thus, the parameter estimates (effect in the absence of drug \(E_{max}\), maximal drug effect \(E_{max}\), 50% effective concentration \(EC_{50}\), and Hill coefficient) for the inhibitory sigmoid dose-effect model linking the AUC\(_{0-24}/\text{MIC}\) ratio (i.e., for the total plasma colistin concentration) with the magnitude of effect in the murine models (unpublished data from references 12 and 13) were used in the current translational analysis. Assuming similar plasma unbound fractions in mice and humans, it was possible to use the human AUC\(_{0-24}\) values predicted using the maintenance dosing algorithm, the respective MICs, and parameter estimates from the murine models to predict the net logs of effect in the murine models. The results of such an analysis for *A. baumannii* in murine thigh infection are shown in Fig. 5; the graph contains AUC\(_{0-24}/\text{MIC}\) values for 105 critically ill patients × 3 strains; 315 data points representing predicted effects relative to the respective baseline inocula. Results for similar analyses performed for the same strains of *A. baumannii* in a murine lung infection model (13) and for 3 strains of *P. aeruginosa* studied in neutropenic mice with infected thighs and lungs (12) are presented in Table 4. The number of cases corresponding to various predicted magnitudes of effect against each bacterial strain in each murine model is delineated.

The potential consequences of commencing maintenance therapy with CMS in the absence of a loading dose must be considered. Because of slow conversion of the administered prodrug, CMS, to the active antibacterial, colistin, and the long half-life of the latter, accumulation to plasma colistin concentrations likely to be effective takes some time in the absence of a loading dose (31). The slow accumulation of formed colistin in plasma was also evident in the population PK model fits in this study (Fig. 3). We used the fitted model to determine the appropriate mean loading dose of CMS to more rapidly achieve steady-state plasma concentrations of formed colistin. A Monte Carlo simulation (ADAPT 5) (9) was performed, simulating 9,999 randomly selected patients using parameters and distributions achieved in our study. Equation 9 (Table 3) represents the loading dose required to achieve a desired plasma colistin \(C_{ss,avg}\) target; the loading dose should be calculated using the lower of ideal or actual body weight and would be administered on day one, followed by commencement 24 h later of the relevant maintenance dosage regimen (Table 3).

**DISCUSSION**

Data supporting dosing recommendations for CMS from prospective studies continue to be scarce. Although some data describing the PK of CMS and formed colistin in critically ill patients are available (29, 31), the studies included only 14 and 18 patients, respectively, and all 32 patients had creatinine clearance values greater than 40 ml/min; none of the patients was in receipt of renal replacement therapy. Thus, the patient populations were not representative of the full range of critically ill patients who may require intravenous administration of CMS for treatment of a Gram-negative infection. Neither of
these previous studies (29, 31) provided maintenance dosing suggestions for CMS in critically ill patients. The current study describes the disposition of the prodrug, CMS, and formed colistin in 105 critically ill patients, including 12 on intermittent hemodialysis and 4 on continuous renal replacement therapy. Of the 105 patients, 69 had CrCL of less than 40 ml/min/1.73 m². Based upon population PK analysis and a thorough search for covariates in the disposition of CMS and formed colistin, we have been able to develop dosing suggestions for various categories of critically ill patients.

Across the two previous PK studies of critically ill patients (29, 31), 30 patients received a CMS dose of 9 million units (MU) per day, while the remaining two patients received 6 and 4 MU per day; this corresponds to a range of CBA doses of about 120 to 270 mg/day, although clearly the majority of patients received the highest dose. In the present study, there was a 5.5-fold range in the physician-selected daily dose of CMS (75 to 410 mg CBA) across the patients, with a clear difference in the physician-selected daily dose that was converted to colistin. The results from the current study to mirror the one used by Plachouras et al. (31); the intersubject variability of 59% in the earlier study (31).

Renal function, expressed as CrCL, was an important covariate for the clearance of both CMS and colistin in our population PK model. In renally healthy individuals, the prodrug, CMS, is predominantly cleared by renal excretion, with only a relatively small fraction of a dose converted to the active antibacterial, colistin (23, 26); thus, total clearance of CMS is expected to decline with CrCL. At first thought it may seem surprising that CrCL was an important covariate for the clearance of formed colistin, because following direct administration of colistin in animal studies, it is cleared predominantly by nonrenal mechanisms, with only a very small fraction of the administered dose recovered in urine in unchanged form (24, 26). The explanation for CrCL being a covariate for the apparent clearance of formed colistin in this study lies in the somewhat unusual overall disposition of CMS and formed colistin. As mentioned above, only a small fraction of an ad-

### Table 4. Pharmacodynamic activity predicted by applying AUC\(_{0-24}\) values for each of 105 critically ill patients together with PD parameters from 3 isolates of \(A.\) baumannii and 3 isolates of \(P.\) aeruginosa in murine thigh and lung infection models

<table>
<thead>
<tr>
<th>Study (reference)</th>
<th>Strain</th>
<th>MIC (mg/liter)</th>
<th>% of cases corresponding to predicted magnitude of effect</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>&lt; stasis</td>
</tr>
<tr>
<td>(P.) aeruginosa murine thigh infection (12)</td>
<td>19056</td>
<td>0.5</td>
<td>13.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>78.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>95.2</td>
</tr>
<tr>
<td>(P.) aeruginosa murine lung infection (12)</td>
<td>19056</td>
<td>0.5</td>
<td>1.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>36.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>24.8</td>
</tr>
<tr>
<td>(A.) baumannii murine thigh infection (13)</td>
<td>248-01-C.248</td>
<td>1</td>
<td>12.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.5</td>
<td>7.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>0.0</td>
</tr>
<tr>
<td>(A.) baumannii murine lung infection (13)</td>
<td>248-01-C.248</td>
<td>1</td>
<td>18.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.5</td>
<td>1.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>0.0</td>
</tr>
</tbody>
</table>

\(AUC_{0-24}\) values are from algorithm-predicted maintenance doses targeting a colistin \(C_{\text{ss,avg}}\) of 2.5 mg/liter.

Unpublished PD parameter estimates referenced to the total plasma colistin concentration from references 12 and 13.

Percentage of cases (105 patients) corresponding to various predicted effects relative to the respective baseline inocula.
ministered dose of CMS is converted to colistin (23); since CMS is cleared predominantly by renal excretion, as CrCL declines a progressively larger fraction of a dose of CMS will be converted to colistin, although we cannot discount the possibility of an associative decrease in the actual clearance of colistin as renal function declines. The practical consequence of this rather complex interplay of dispositional processes for administered CMS and formed colistin and the impact of renal function thereon are clearly evident in Fig. 2. Not surprisingly, CrCL was the major PK factor involved in the CMS maintenance dosing algorithm for generation of a target plasma concentration of formed colistin (Table 3, equation 10). Neither of the previous PK studies of critically ill patients found CrCL to be a covariate for the clearance of formed colistin (29, 31); similarly, CrCL was not a covariate for the clearance of administered CMS (31). It is very likely that the inability to detect relationships between renal function and clearances of CMS and colistin in the previous studies was the result of the small sample sizes (14 and 18 patients) and the relatively narrow range of CrCL values (>40 ml/min) for the enrolled patients (29, 31). We also found body size to be a relevant covariate affecting the volume of the central compartment for CMS; as a consequence, suggested CMS loading doses are a function of body weight (Table 3). We did not, however, find any significant trends in clearance of either CMS or colistin against body size, and thus we were not able to propose a weight-based maintenance dosing algorithm for CMS.

Since the physician-selected CMS maintenance doses in this study provided a substantive variance in AUC_{0-24} (and corresponding C_{ss,avg}) for colistin (Fig. 1), we developed a dosing algorithm incorporating renal function to estimate the suggested CMS maintenance dose (expressed as mg CBA per day) required to reach a target C_{ss,avg} for colistin (Table 3, equation 10). CrCL as a covariate explained ~60% of the variability in the “ideal” maintenance dose of CBA required to achieve a given target C_{ss,avg} for colistin (Fig. 4). Further improving on this precision would require identification of additional PK covariates and/or development of an adaptive feedback control algorithm for colistin (individual optimization based on PK/PD/TD principles). The maintenance dosing algorithm performed satisfactorily when it was applied to patients not on any renal replacement and those on HD, using a colistin C_{ss,avg} target of 2.5 mg/liter, corresponding to a steady-state colistin AUC_{0-24} of 60 mg • h/liter. Similarly, the suggested CMS maintenance dose for patients on CRRT (Table 3) performed well when applied to the 4 patients in this category.

It is noteworthy that the CMS maintenance dose required to achieve each 1.0 mg/liter of the colistin C_{ss,avg} target in patients on CRRT (192 mg CBA per day) (Table 3) is very similar to that required in a patient with a CrCL of ~100 ml/min/1.73 m² (Table 3, equation 10). This may seem surprising given that colistin is predominantly nonrenally cleared in individuals with normal kidney function (26). The explanation most likely relates to the mechanisms involved in the renal handling of colistin in the presence of intact kidney function in comparison with the extracorporeal clearance mechanisms in operation in CRRT. The renal handling of colistin involves very extensive tubular reabsorption; this serves to retain in the body a very large fraction of the filtered load of colistin, and it contributes to an extremely low fraction excreted unchanged in urine (24, 26). In contrast, following clearance by diffusion and/or convection in a CRRT cartridge, there is no carrier-mediated mechanism to return colistin from dialysate to blood perfusing the cartridge.

This and other (15, 28) studies have also shown that CMS and colistin are efficiently cleared during intermittent HD; the magnitudes of extracorporeal clearances of CMS and colistin in this study are in accord with those reported elsewhere (15, 28). Even when a dialysis session occurs toward the end of a CMS dosage interval, a substantial amount of CMS and colistin would be cleared, necessitating a supplemental dose of CMS to maintain a colistin C_{ss,avg} similar to that occurring on a nondialysis day; a larger supplemental dose would be required if administered during dialysis compared with dosage after the session (Table 3). Because of the large fluctuations in plasma CMS concentrations during a dosage interval (Fig. 1), a much larger amount of CMS would be cleared if dialysis occurs early in a dosage interval. For this reason, it is suggested that dialysis is best conducted toward the end of a CMS dosage interval.

It is important to provide caveats about the loading and maintenance dose suggestions for CMS in Table 3. When computing the absolute loading dose of CBA from the result of applying equation 9 (Table 3), the lower of either the actual or ideal body weight should be used. In addition, there is little experience with using (single daily) doses of CMS greater than the current upper limit in the product information (300 mg CBA), and the potential impact of large loading doses of CMS on renal function is not known. Thus, at this time we suggest caution in the use of a loading dose greater than 300 mg CBA. In relation to suggested maintenance doses, the algorithm (Table 3, equation 10) predicts the need for increasingly high CMS maintenance doses as CrCL increases, and dependent upon the desired colistin C_{ss,avg}, this may generate suggested CMS daily doses above the upper limit (300 mg CBA per day) in the current product labeling (2). For example, if targeting a colistin C_{ss,avg} of 2.5 mg/liter, a patient with a CrCL of 70 ml/min/1.73 m² would require 337.5 mg CBA per day. In such patients (i.e., with moderate to good renal function), it is theoretically possible to use daily doses of CMS higher than 300 mg CBA per day to generate a desired target colistin C_{ss,avg} similar to those occurring with lower maintenance doses of CMS in patients with poorer kidney function (Fig. 2). However, increasing the daily dose of CBA beyond the current upper limit daily dose in patients with relatively good renal function comes at the expense of presenting a larger mass of CMS to the kidneys, with the potential for intrarenal conversion to colistin (23), which may increase the possibility of nephrotoxicity. This is not an insignificant risk given the rate of nephrotoxicity even with the currently recommended CMS dosage regimen. In the present study, of the 89 patients not on renal replacement, all but two had been prescribed a CMS maintenance dose of 300 mg CBA per day or less, and 43/89 (48%) had a rise in serum creatinine of >50%, of which, for 27/43 (63%), levels remained elevated at the end of the study; these findings are similar to those reported for other studies (10, 16). Thus, care is needed in the use of the maintenance dosing algorithm for patients with moderate to good renal function and/or when it is desired to target a relatively high colistin C_{ss,avg} target, circumstances where the algorithm-suggested daily dose of CBA may be sub-
stantially greater than 300 mg/day. At this time, we do not
recommend use of the algorithm for patients with CrCL of
>70 ml/min/1.73 m² unless it is appropriate to target a low
C_{ss,avg} of colistin.

The PK data for critically ill patients obtained in the current
study were integrated with PD data for *A. baumannii* and *P. aeruginosa* in murine thigh and lung infection models (12–13). In undertaking these translational analyses, because of the
absence of information on plasma binding of colistin in criti-
cally ill patients, we utilized PD parameter estimates for total
(i.e., unbound plus bound) colistin in plasma in the murine
models and linked them with the colistin C_{ss,avg} (i.e., total
plasma concentration) expected to be achieved in the individ-
cually critically ill patients from algorithm-predicted maintenance
doses targeting a colistin C_{ss,avg} of 2.5 mg/liter. This approach
assumes that the “average” unbound fraction in infected mice
is similar to that in infected humans. We chose a colistin C_{ss,avg}
of 2.5 mg/liter (corresponding to a target AUC_{0-24} of 60 mg
· h/liter) for two reasons: first, it was similar to the median
C_{ss,avg} of 2.36 mg/liter in the 105 patients with the physician-selected
maintenance doses of CMS; second, against 3 strains each of *A.
baumannii* and *P. aeruginosa* in murine thigh and lung infection
models, a ratio of AUC_{0-24} to MIC of 60 was generally asso-
ciated with an effect somewhere between stasis and 1-log kill,
with the exception of *P. aeruginosa* in thigh infection, where a
smaller effect was observed (unpublished data from references
12 and 13 for data based on the total plasma colistin concen-
tration). From the results of these analyses, it appears that
the above maintenance doses (and resultant colistin C_{ss,avg}) would
not be reliably effective against isolates with MICs greater than
0.5 mg/liter (Fig. 5 and Table 4). It is our opinion that in order
to achieve dosages regimes with a high probability of safety
and efficacy, it appears that colistin might best be used as part
of a highly active combination. This is especially likely to be
the case for patients with moderate to good renal function, for
whom, as discussed above, it is not possible to achieve colistin
C_{ss,avg} values that are likely to be reliably effective without
administration of maintenance doses of CMS which may in-
crease the risk of nephrotoxicity.

In conclusion, this is the first study to report the results of
population PK modeling for more than 100 critically ill pa-
tients with a diverse range of renal functions, including those
requiring intermittent hemodialysis or continuous renal re-
placement therapy. Our modeling revealed that creatinine
clearance was an important covariate in the clearance of both
CMS and formed colistin. As a result, we have developed the
first scientifically based dosing suggestions for CMS to gener-
ate a desired target steady-state plasma concentration of
formed colistin in various categories of critically ill patients.
Our current results suggest that because of the inability to
achieve adequate plasma concentrations of formed colistin
with CMS monotherapy, CMS/colistin might best be used as
part of a highly active combination, especially when treating an
infection caused by an organism with an MIC of >0.5 mg/liter
in a patient with a creatinine clearance of >70 ml/min/1.73 m².
The loading and maintenance dosing suggestions reported
herein should be regarded as interim; they will be refined as we
complete recruitment to a total of 238 critically ill patients
and also model the pharmacodynamic and toxicodynamic end-
points.

ACKNOWLEDGMENTS

The work described was supported by award no. R01AI070896 from
the National Institute of Allergy and Infectious Diseases. J.L. is an
Australian National Health and Medical Research Council Senior
Research Fellow.

The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institute of
Allergy and Infectious Diseases or the National Institutes of Health.
We are grateful to the patients and their families. The dedication of
the research support staff at the various study sites, in particular Diana
Lynn Pakstis, Mary Ellen Carey, Peerawong Weraarak, Sunee
Thanakumtorn, and Laksmi Wattanamongkol, is gratefully ac-
knowledged. The advice of John Kellum is noted with gratitude. We
thank Juergen Bulitta for his assistance with the evaluation of the
total population pharmacokinetic model via bootstrap techniques.
We do not have any financial, commercial, or proprietary interest in
any drug, device, or equipment mentioned in this article.

REFERENCES

1. Antoniadou, A., et al. 2007. Colistin-resistant isolates of Klebsiella pneu-
moniae emerging in intensive care unit patients: first report of a mul-
2. APP Pharmaceuticals LLC. 2008. Colistimethate. Package insert. APP Phar-
macueticals LLC, Schaumburg, IL.
3. Bauer, R. J., S. Guzy, and C. Ng. 2007. A survey of population analysis
methods and software for complex pharmacokinetic and pharmacodynamic
5. Beal, S. L. 2001. Ways to fit a PK model with some data below the quanti-
patients caused by colistin-resistant Gram-negative bacilli after previous
sulfonate is an inactive prodrg of colistin against Pseudomonas aeruginosa.
and evaluation of a new efficiency tool (SADAPT-TRAN) for model cre-
dation, debugging, evaluation, and automated plotting using parallelized-
S-ADAPT. Perl and R. abstr. 1917. 19th Population Approach Group in
Europe, Berlin, Germany.
pharmacokinetic/pharmacodynamic systems analysis software. Biomedical
Computations Resource, University of Southern California, Los Angeles, CA.
dosing and nephrotoxicity in a large community teaching hospital. Antimi-
colistin and colistin methanesulfonate in human plasma under different
12. Dudhani, R. V., et al. 2010. Elucidation of the pharmacokinetic/pharmacody-
namic determinant of colistin activity against Pseudomonas aeruginosa in
54:1117–1124.
13. Dudhani, R. V., J. D. Turnidge, R. L. Nation, and J. Li. 2010. IAUC/MIC is
the most predictive pharmacokinetic/pharmacodynamic index of colistin
against Acinetobacter baumannii in murine thigh and lung infection models.
for the management of multidrug-resistant gram-negative bacterial infec-
renal or liver disease. Abstr. 50th Intersci. Conf. Antimicrob. Agents Che-
Quantitative analysis of colistin A and colistin B in plasma and culture
medium using a simple precipitation step followed by LC/MS/MS. J. Pharm.
over the past few years. Chest 119:4078–404S.
Vol. 55, 2011 CMS AND COLISTIN POPULATION PK IN CRITICALLY ILL PATIENTS 3293


